Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Account Payables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Change in Account Payables for 12 consecutive years, with $979000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 130.46% to $979000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$190000.0 through Dec 2025, up 94.0% year-over-year, with the annual reading at -$190000.0 for FY2025, 94.0% up from the prior year.
  • Change in Account Payables for Q4 2025 was $979000.0 at ImmunityBio, up from -$1.4 million in the prior quarter.
  • The five-year high for Change in Account Payables was $6.5 million in Q1 2021, with the low at -$8.9 million in Q3 2024.
  • Average Change in Account Payables over 5 years is -$277500.0, with a median of -$477500.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables plummeted 758.35% in 2023, then surged 545.81% in 2024.
  • Over 5 years, Change in Account Payables stood at -$3.5 million in 2021, then surged by 112.32% to $437000.0 in 2022, then tumbled by 758.35% to -$2.9 million in 2023, then decreased by 11.71% to -$3.2 million in 2024, then surged by 130.46% to $979000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $979000.0, -$1.4 million, and -$6.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.